FPAS
NBIX icon

Focus Partners Advisor Solutions’s Neurocrine Biosciences NBIX Stock Holding History

Focus Partners Advisor Solutions’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Sell
11,434
-7,184
-39% -$1.07M 0.02% 374
2026
Q1 		$2.45M Buy
18,618
+4,074
+28% +$541K 0.02% 309
2025
Q4 		$2.06M Buy
14,544
+1,281
+10% +$186K 0.03% 303
2025
Q3 		$1.94M Buy
13,263
+8,011
+153% +$1.09M 0.02% 345
2025
Q2 		$660K Buy
+5,252
New +$602K 0.01% 585

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Focus Partners Advisor Solutions's NBIX Position: Q2 2026 in Review

Focus Partners Advisor Solutions reduced its Neurocrine Biosciences (NBIX) stake by 39% in Q2 2026, selling an estimated $1.07M and leaving 11,434 shares worth $1.93M. The position accounts for 0.02% of the portfolio, ranked #374.

Focus Partners Advisor Solutions first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.45M in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Focus Partners Advisor Solutions held 11,434 shares of Neurocrine Biosciences worth $1.93M as of Q2 2026.
  • Focus Partners Advisor Solutions sold 7,184 Neurocrine Biosciences shares in Q2 2026, an estimated $1.07M.
  • Neurocrine Biosciences made up 0.02% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #374 holding.
  • Focus Partners Advisor Solutions first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Focus Partners Advisor Solutions's Neurocrine Biosciences position peaked at $2.45M in Q1 2026.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.